Table 2 Summary of FAK inhibitors in clinical trials
From: Focal adhesion kinase: from biological functions to therapeutic strategies
Name | Alternative names | Target(s) | Cancer types | Status | Phase | NCT number |
|---|---|---|---|---|---|---|
VS-6063 | Defactinib, PF-04554878 | FAK, Pyk2 | Advanced non-hematologic Malignancies | Completed | 1 | NCT00787033 |
Non-hematologic cancer | Completed | 1 | NCT01943292 | |||
NSCLC | Completed | 2 | NCT01951690 | |||
Recurrent skin cancer, squamous cell carcinoma of the skin, stage 0 chronic lymphocytic leukemia, stage I chronic lymphocytic Leukemia | Completed | 2 | NCT00563290 | |||
Ovarian cancer | Completed | 1 | NCT01778803 | |||
Solid tumor, pancreatic cancer | Completed | 1 | NCT02546531 | |||
NSCLC, low grade serous ovarian cancer, endometrioid carcinoma, pancreatic cancer | Recruiting | 1 | NCT03875820 | |||
Metastatic uveal melanoma | Recruiting | 2 | NCT04720417 | |||
Pancreas cancer | Recruiting | 2 | NCT04331041 | |||
Ovarian cancer | Recruiting | 1 2 | NCT03287271 | |||
PDAC | Recruiting | 2 | NCT03727880 | |||
Advanced lymphoma, advanced malignant solid neoplasm, hematopoietic and lymphoid cell neoplasm, refractory lymphoma, refractory malignant solid neoplasm, refractory plasma cell myeloma | Active, not recruiting | 2 | NCT04439331 | |||
Glioma | Not yet recruiting | Early 1 | NCT05798507 | |||
Malignant pleural mesothelioma | Terminated | 2 | NCT02004028 | |||
CRC | Terminated | Early 1 | NCT00835679 | |||
Relapsed malignant mesothelioma | Terminated | 1 | NCT02372227 | |||
NSCLC, mesothelioma, pancreatic neoplasms | Unknown status | 1 2 | NCT02758587 | |||
BI 853520 | IN10018, ifebemtinib | FAK | Neoplasms | Completed | 1 | NCT01335269 |
Gastric cancer | Completed | 1 | NCT05327231 | |||
Metastatic melanoma | Recruiting | 1 | NCT04109456 | |||
Pancreatic cancer | Recruiting | 1 2 | NCT05827796 | |||
Platinum-resistant ovarian cancer | Recruiting | 1 2 | NCT05551507 | |||
Locally advanced or metastatic solid tumor | Active, not recruiting | 1 2 | NCT05830539 | |||
Solid tumor | Not yet recruiting | 1 2 | NCT05379946 | |||
GSK2256098 | – | FAK | Solid tumor | Completed | 1 | NCT01138033 |
Cancer | Completed | 1 | NCT00996671 | |||
Pancreatic cancer, adenocarcinoma | Completed | 2 | NCT02428270 | |||
Advanced solid tumor | Completed | 1 | NCT01938443 | |||
Intracranial meningioma, recurrent meningioma, Nf2 gene mutation | Recruiting | 2 | NCT02523014 | |||
VS-4718 | PND-1186 | FAK, Pyk2 | Pancreatic cancer | Terminated | 1 | NCT02651727 |
Non-hematologic cancer, metastatic cancer | Terminated | 1 | NCT01849744 | |||
Relapsed or refractory acute myeloid leukemia, relapsed or refractory B-cell acute lymphoblastic leukemia | Withdrawn | 1 | NCT02215629 | |||
CT-707 | Conteltinib | FAK, ALK, Pyk2 | Advanced pancreatic cancer | Recruiting | 1 2 | NCT05580445 |
NSCLC | Unknown status | 1 | NCT02695550 | |||
VS-6062 | PF-00562271 | FAK, Pyk2 | Head and neck neoplasm, prostatic neoplasm, pancreatic neoplasm | Completed | 1 | NCT00666926 |
AMP-945 | Narmafotinib | FAK | PDAC | Recruiting | 1 2 | NCT05355298 |
APG-2449 | – | FAK, ALK, ROS1 | Advanced solid cancer, NSCLC, esophageal cancer, ovarian cancer, malignant pleural mesothelioma | Recruiting | 1 | NCT03917043 |